Sun Pharma licenses global rights to LIB Therapeutics' cholesterol drug lerodalcibep

The agreement gives Sun Pharma rights to the once-monthly PCSK9 inhibitor lerodalcibep across global markets excluding the US and China.

Sun Pharma has secured exclusive licensing, commercialisation and manufacturing rights to LIB Therapeutics' lerodalcibep worldwide outside the US and China.

The deal adds an EU-approved once-monthly PCSK9 inhibitor, marketed as Lyrokaul in Europe, to Sun Pharma's portfolio in exchange for undisclosed upfront and milestone payments plus royalties.

Field	Content
Field	Content
Alert Type	Licensing Agreement
Companies	Sun Pharma; LIB Therapeutics
Deal Type	Exclusive licensing, commercialisation and manufacturing agreement
Asset	Lerodalcibep
Brand	Lyrokaul in the European Union
Therapy Area	Cardiovascular disease / lipid management
Target	PCSK9
Technology/Modality	Once-monthly injectable PCSK9 inhibitor
Geography	Worldwide excluding the US and China
Deal Value	Financial amounts not disclosed
Deal Economics	Upfront payment, milestone payments and royalties
What Happened	Sun Pharma secured exclusive rights to lerodalcibep in markets worldwide excluding the US and China.
Why It Matters	The transaction gives Sun Pharma access to a differentiated once-monthly cholesterol-lowering therapy with an existing European regulatory approval.
Strategic Rationale	The agreement expands Sun Pharma's cardiovascular portfolio and provides a platform for commercialising lerodalcibep across multiple international markets.
Potential Impact	The partnership could broaden global access to lerodalcibep while strengthening Sun Pharma's position in lipid management.
Key Takeaway	Sun Pharma gains broad international rights to LIB Therapeutics' once-monthly PCSK9 inhibitor.
What to Watch	Market launches, reimbursement decisions and commercial uptake outside the US and China.
Primary Source	Sun Pharma
Relevant Date	28 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com